Table 3.

Summary of phase 3 trial results in relapsed/refractory CLL

Trial	Agents	Design	Number	Median age	Median PFS (months)	Median follow-up (months)	MRD
REACH [2]	FCR vs. FC	Open label	552	62.5	30.6 vs. 20.6 months (p < 0.001)	25	13 vs. 12%
RESONATE [37]	Ibrutinib vs. ofatumumab	Open label	391	67	Not reached vs. 8.1 months	9.4	n/a
Furman 2014 [52]	Idelalisib + rituximab vs. rituximab	Double-blind	220	71	Not reached vs. 5.5 months	3.8 and 2.9a	n/a
HELIOS [74]	Ibrutinib + BR vs. BR	Double-blind	578	63.5	Not reached vs. 13.3 (p < 0.0001)	17	18 vs. 5% (p = 0.0011)
Zelenetz 2015 [75]	Idelalisib + BR vs. BR	Double-blind	416	58% <65 years	23 vs. 11 (p < 0.0001)	12	n/a
COMPLEMENT 2 [19]	Ofatumumab + FC vs. FC	Open label	365	61	28.9 vs. 18.8 (p = 0.0032)	34	21 vs. 8% (p = 0.0006)
Jones 2016 [76]	Idelalisib + ofatumumab vs. ofatumumab	Open label	261	67	16.4 vs. 8.0 (p < 0.0001)	12.3	n/a

^aTime receiving study drug